Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial.
Akihiko KoshinoMegumi OshimaClare ArnottRobert A FletcherGeorge L BakrisMeg JardineKenneth W MahaffeyVlado PerkovicCarol PollockHiddo J Lambers HeerspinkBrendon L NeuenPublished in: Diabetes, obesity & metabolism (2023)